Doi, Toshihiko
Yang, James Chih-Hsin
Shitara, Kohei
Naito, Yoichi
Cheng, Ann-Lii
Sarashina, Akiko
Pronk, Linda C.
Takeuchi, Yoshito
Lin, Chia-Chi
Funding for this research was provided by:
Boehringer Ingelheim
Article History
First Online: 6 February 2019
Compliance with Ethical Standards
:
: This trial was sponsored by Boehringer Ingelheim. Open Access publication for this article was funded by Boehringer Ingelheim.
: James Chih-Hsin Yang has consulted for and received honoraria from Eli Lilly, Boehringer Ingelheim, Bayer, Roche/Genentech, Chugai, Astellas, MSD, Merck Serono, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, BMS, Ono Pharmaceutical Co., Ltd., Daiichi Sankyo, AstraZeneca, Takeda, and Hansoh Pharmaceuticals. Kohei Shitara has consulted for or received honoraria from Astellas Pharma, Lilly, BMS, Takeda, Pfizer, Ono Pharmaceutical Co., Ltd., Novartis, AbbVie, and Yakult, and also reports research funding from Lilly, Ono Pharmaceutical Co., Ltd., Dainippon Sumoitomo Pharma, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharma, and MSD. Ann-Lii Cheng has consulted for or received honoraria from Bayer, BMS, Eisai, MSD, Merck, Novartis, BeiGene, and Ono Pharmaceutical Co., Ltd. Akiko Sarashina and Yoshito Takeuchi are employees of Nippon Boehringer Ingelheim Co., Ltd. Linda C. Pronk is an employee of Boehringer Ingelheim. Toshihiko Doi, Yoichi Naito, and Chia-Chi Lin declare that they have no conflicts of interest. This trial was sponsored by Nippon Boehringer Ingelheim. Co., Ltd. in Japan, and Boehringer Ingelheim Taiwan Ltd. in Taiwan. This work was supported by Boehringer Ingelheim, Ingelheim am Rhein, Germany. BI 853520 is an asset of Boehringer Ingelheim.